TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04338750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Acceptance and Commitment Therapy Intervention for Caregivers
Description: Participants randomized to TACTICs will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1-hour sessions by a trained Bachelor's-level interventionist. Participants in this intervention will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' caregiving experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to anxiety and caregiving challenges. Participants will receive handouts on session topics and a CD with guided mindfulness practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: minimally-Enhanced Usual Care
Description: Participants randomized to mEUC will receive a letter thanking them for participating in the trial along with the Alzheimer's Caregiving guide from the National Institute of Aging of the National Institutes of Health (https://www.nia.nih.gov/health/alzheimers/caregiving), coupled with a listing of the five Alzheimer's Association sponsored support groups closest to their home address.
Study: NCT02844556

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SMILE surgery
Description: SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.

Intervention type: OTHER
Group type: OTHER
Intervention: FS-LASIK surgery
Description: SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
Study: NCT01697735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine;Atorvastatin or Rosuvastatin
Description: Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin or Rosuvastatin
Description: Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
Study: NCT03641664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Centered Treatment
Description: Family Centered Treatment® (FCT) is a promising practice for providing home-based services to families at-risk for their children being removed from home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Level II or Level III Out of Home Placement
Description: Residential care for children with emotional, behavioral, and/or mental health in North Carolina who have experienced a level of dysfunction that makes it impossible to function at an age appropriate level in their own homes or in a lower level of care. These services can be provided in a variety of locations from urban to rural, from facility based to community based and from public sector to private sector. This service provides a structured and supervised environment for the acquisition of skills necessary to enable the child to improve level of functioning to achieve and/or to maintain the most realistic level of independent function where earlier treatment gains are somewhat fragile and the child is subject to regression.
Study: NCT02097615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate
Description: chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks

Intervention type: OTHER
Group type: OTHER
Intervention: deionized water
Description: application every 24 hours six weeks
Study: NCT01487798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
Study: NCT02202759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0264
Description: MLN0264 IV infusion
Study: NCT03297112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Subharmonic Ultrasound Imaging
Description: Undergo contrast-enhanced subharmonic ultrasound imaging
Study: NCT00844961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered cognitive behavior therapy
Description: 10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
Study: NCT02494323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
Study: NCT01963416

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: macro- and micro-nutrient matched control (240 ml)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole orange fruit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed whole orange
Study: NCT01422343

Intervention type: PROCEDURE
Intervention: percutaneous transluminal angioplasty femoro-popliteal
Description: percutaneous transluminal angioplasty femoro-popliteal
Study: NCT02461641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NuShield
Description: NuShield is a sterilized dehydrated amnion chorion membrane patch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affinity
Description: Affinity is a aseptically produced hypothermically stored amniotic membrane patch.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
Study: NCT04400201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance
Study: NCT00512915

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pacemaker implantation
Description: St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pacemaker implantation
Description: St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
Study: NCT02230995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: single dose of metformin given as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin/metformin
Description: Single dose empagliflozin/metformin given as fixed-dose combination tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: single dose of empagliflozin given as tablet
Study: NCT00218868

Intervention type: PROCEDURE
Intervention: Skin scrape
Description: scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
Study: NCT03584477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot InMotion 2.0
Description: Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot InMotion 2.0
Description: Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
Study: NCT01886066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Description: ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. One 25 mg vial of ICG will be reconstituted in 10 mL of aqueous solvent (2.5 mg/mL). The solution will be injected at the 3 and 9 o'clock positions of the cervical stroma. 0.5 mL is injected superficially (submucosa) and 0.5 mL is injected deep (\~8mm) in the cervical stroma for a total injection volume of 2 mL.
Study: NCT00335777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migranal nasal spray at 1 hour
Description: Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migranal nasal spray at 4 hour
Description: Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
Study: NCT02446574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: starting dose 20mg/m2 qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: dose 25mg/m2 qw

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 60Gy/2Gy/30f
Study: NCT04775940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perforated collagen membrane
Description: Horizontal Bone Augmentation using Perforated Collagen Membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive collagen membrane
Description: Occlusive collagen membrane
Study: NCT02079246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg
Description: once daily, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg
Description: once daily, encapsulated tablets, orally
Study: NCT02331212

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01209416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acipimox
Description: Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acipimox
Description: Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Ghrelin infusion 4.2 ng/kg/min throughout the investigation day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Ghrelin infusion 4.2 ng/kg/min throughout the investigation day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo tablets or saline infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo tablets or saline infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets or saline infusion
Study: NCT02189317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
Study: NCT04035460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet
Description: The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Oxygen
Description: Large-bore nasal prongs through which oxygen is delivered at high flow rates
Study: NCT02419001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 - Treatment Sequence AB
Description: Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 - Treatment Sequence AC
Description: Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Treatment Sequence AB
Description: Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Treatment Sequence AC
Description: Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
Study: NCT04876378

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT03774238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMD analysis
Description: Blood sample and vascular exploration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMD analysis
Description: Blood sample and vascular exploration.
Study: NCT01209052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
Study: NCT01385033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-3328
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-3328
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-3328
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
Study: NCT03209570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care planning using TENA Identifi sensor wear data
Description: All individuals in this arm will receive TENA Identifi sensor wear and will have data available for care planning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care planning without using TENA Identifi sensor wear data
Description: All individuals in this arm will receive TENA Identifi sensor wear but the sensor wear data will not be used for care planning.
Study: NCT03975985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises (CSE)
Description: CSE are exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (physioball). The exercise involves changes in the position of the body without resistance, aiming to improve strength, endurance, proprioception and coordination.~- TENS: Half of the patients assigned to CSE will also receive TENS (highfrequency TENS 100 Hz; 0.2 ms pulse width), administered via TENS stimulator with two disposable 0.9 mm diameter electrodes placed on the skin over the lumbar erector spinae (3 cm lateral to the L3 and L5 spinous process).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: The common feature of CP is that it consists of a management by the physiotherapist according to the CP may consist in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
Study: NCT00890877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459 or placebo
Description: Pills, active and/or placebo given twice daily for 17 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459 or placebo
Description: Pills, active and/or placebo given twice daily for 17 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459 or placebo
Description: Pills, active and/or placebo given twice daily for 17 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459 or placebo
Description: Pills, active and/or placebo given twice daily for 17 weeks
Study: NCT04471207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapist Guided Prolonged Exposure with BioWare Device
Description: Experimental: Intelligent Biometrics - Prolonged Exposure (therapist guided). In the therapist guided group, Study Therapists will use actionable data during in vivo exposures (IVEs) (galvanic skin response \[GSR\], heart rate \[HR\], and subjective units of distress \[SUDS\]) to modify the assignments in real-time.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Record Only Prolonged Exposure with BioWare Device
Description: In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder.
Study: NCT03736109

Intervention type: GENETIC
Intervention: Soluble and genetic biomarkers measurements
Description: Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA

Intervention type: GENETIC
Intervention: Soluble and genetic biomarkers measurements
Description: Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
Study: NCT02605109

Intervention type: OTHER
Intervention: Risk of MERS infection
Description: HCPs, patients and layperson to closely or indirectly contact a case-patients